Bayer – Talk Bio

Bayer Stock Rallies as Next-Gen Blood Thinner Achieves Phase 3 Success

2 weeks ago talkbio0Tagged Bayer, blood thinner, earnings, Phase 3 trial, rally

Bayer; stock rally; blood thinner; Phase 3 trial; pharmaceuticals; earnings

Bayer’s Pharma Division Grows as Restructuring Drives Major Changes

4 weeks ago talkbio0Tagged Administration occupational activities, Bayer, DSO, Dynamic Shared Ownership, Kerendia, Neoplasms, Nubeqa, pharma division, restructuring, Sales growth, Xarelto

Bayer; pharma division; restructuring; job cuts; Dynamic Shared Ownership (DSO); sales growth; oncology; Kerendia; Nubeqa; Xarelto; management changes

Bayer Receives FDA Approval for Lynkuet, a Novel Non-Hormonal Drug for Menopausal Hot Flashes

1 month ago talkbio0Tagged Approved, Bayer, Elinzanetant, Hot flushes, Lynkuet, Menopause, NK1/NK3 receptors, Non-Hormonal, United States Food and Drug Administration, vasomotor symptom

Bayer; FDA approval; Lynkuet; elinzanetant; hot flashes; menopause; non-hormonal; NK1/NK3 receptors; vasomotor symptoms

FDA Approves Bayer’s Lynkuet for Menopausal Hot Flashes

1 month ago talkbio0Tagged Approved, Bayer, Hot flushes, Lynkuet, Menopause, United States Food and Drug Administration

FDA approval; Bayer; Lynkuet; menopause; hot flashes

Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal

4 months ago talkbio0Tagged Approved, Bayer, Cancer Therapeutic Procedure, commercialization, G12D inhibitor, K-ras Oncogene, Kumquat Biosciences, milestone payments, Oncology Pipeline, precision oncology, United States Food and Drug Administration

Bayer; Kumquat Biosciences; oncology pipeline; KRAS G12D inhibitor; FDA approval; cancer therapy; precision oncology; commercialization; milestone payments

Bayer-allied NextRNA Therapeutics winds down operations after missing a milestone in their collaboration

4 months ago talkbio0Tagged Bayer, Dana-Farber, Funding, Long Intergenic Non-Protein Coding RNA, Massachusetts biotech, missed milestone, Neoplasms, NextRNA, Series, shutdowns

NextRNA Therapeutics; Bayer; lncRNA; long non-coding RNA; oncology; biotech wind-down; missed milestone; Massachusetts biotech; seed and Series A funding; Dana-Farber; Carl Novina; 2025 biotech shutdowns